Valuation: Novavax, Inc.

Market Cap 1.78B 1.57B 1.48B 1.34B 2.52B 171B 2.54B 17.74B 6.85B 87.26B 6.69B 6.54B 280B P/E 2026 *
-17.3x
P/E 2027 * -48.2x
Enterprise Value 2B 1.76B 1.66B 1.51B 2.83B 192B 2.85B 19.92B 7.69B 97.98B 7.51B 7.35B 315B EV / Sales 2026 *
5.36x
EV / Sales 2027 * 7.83x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day+4.26%
1 week+0.77%
Current month+10.37%
1 month+17.01%
3 months+18.22%
6 months+22.82%
Current year+57.65%
1 week 9.15
Extreme 9.15
9.53
1 month 7.88
Extreme 7.88
9.58
Current year 5.74
Extreme 5.74
9.88
1 year 5.41
Extreme 5.406
9.88
3 years 4.71
Extreme 4.706
13.35
5 years 4.71
Extreme 4.706
13.35
10 years 4.71
Extreme 4.706
13.35
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.26%+0.77% - - 1.78B
-0.02%+3.70%+12.27%+37.12% 49.06B
+0.22%+0.40%+50.91%+37.06% 44.6B
-1.58%+4.66%+359.34%+614.38% 43.24B
+1.70%+0.36%+12.56%+99.27% 41.73B
+0.51%-1.71%+5.18%+46.87% 29.93B
-0.48%-1.32%+23.98%+150.01% 17.19B
+0.08%+9.03%+8.41% - 15.35B
-2.01%-2.30%+26.88%+44.19% 15.54B
+1.97%-3.17% - - 15.11B
Average +0.47%+1.85%+62.44%+146.98% 30.19B
Weighted average by Cap. +0.09%+2.26%+78.12%+161.01%

Financials

2026 *2027 *
Net sales 373M 328M 310M 281M 528M 35.8B 531M 3.71B 1.43B 18.27B 1.4B 1.37B 58.7B 266M 234M 221M 201M 377M 25.55B 379M 2.65B 1.02B 13.04B 999M 978M 41.9B
Net income -108M -94.59M -89.44M -81.13M -152M -10.32B -153M -1.07B -414M -5.27B -404M -395M -16.93B -37.93M -33.36M -31.54M -28.61M -53.73M -3.64B -54.04M -378M -146M -1.86B -142M -139M -5.97B
Net Debt 219M 193M 182M 165M 310M 21.02B 312M 2.18B 842M 10.73B 822M 804M 34.47B 303M 267M 252M 229M 430M 29.11B 432M 3.02B 1.17B 14.85B 1.14B 1.11B 47.73B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
28/09/26 €9.150 -1.72% 3,276
25/09/26 €9.310 +0.65% 531
24/09/26 €9.250 -2.01% 1,808
23/09/26 €9.440 -1.46% 1,775
22/09/26 €9.580 +5.51% 4,725
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.80USD
Average target price
14.00USD
Spread / Average Target
+29.65%

Quarterly revenue - Rate of surprise